Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma

This article was originally published in PharmAsia News

Executive Summary

SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market

You may also be interested in...

Sanofi And Korea’s Hanmi Ink Co-marketing Deal That Could See Sanofi Selling Hanmi’s Irbestin Abroad

Sanofi and Korea’s Hanmi sign a co-marketing agreement that may see both companies marketing Hanmi’s fixed-dose combination products beyond Korea.

Korea’s Dong-A Wins Court Battle Over Rebate-Related Price Cuts

The domestic pharma, in which GSK holds a minority stake, won a key battle with the government while its Korean peer Chong Kun Dang lost a similar case and saw 16 drugs take a price cut.

Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates

As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts